{"pmid":32435867,"title":"Diabetes and COVID-19 : Disease-Management-People.","text":["Diabetes and COVID-19 : Disease-Management-People.","The current pandemic of SARS-CoV2 coronavirus disease 2019 (COVID-19) is a particular challenge for diabetes patients. Diabetes mellitus predisposes to a particularly severe course of the disease and doubles the COVID-19 mortality risk due to pulmonary and cardiac involvement. In addition, diabetes patients often suffer from comorbidities which further worsen clinical outcomes. Glycemic control during infectious diseases is often suboptimal, and antidiabetic drugs and insulin therapy have to be adapted accordingly. On the other hand, access of diabetes patients to outpatient clinics are limited during the ongoing season urging alternative treatment options, particularly the implementation of novel telemedicine strategies. Hence, the opportunity of the COVID 19 crisis should be taken to make a significant step forward in the care for diabetes patients.","Wien Klin Wochenschr","Peric, Slobodan","Stulnig, Thomas M","32435867"],"abstract":["The current pandemic of SARS-CoV2 coronavirus disease 2019 (COVID-19) is a particular challenge for diabetes patients. Diabetes mellitus predisposes to a particularly severe course of the disease and doubles the COVID-19 mortality risk due to pulmonary and cardiac involvement. In addition, diabetes patients often suffer from comorbidities which further worsen clinical outcomes. Glycemic control during infectious diseases is often suboptimal, and antidiabetic drugs and insulin therapy have to be adapted accordingly. On the other hand, access of diabetes patients to outpatient clinics are limited during the ongoing season urging alternative treatment options, particularly the implementation of novel telemedicine strategies. Hence, the opportunity of the COVID 19 crisis should be taken to make a significant step forward in the care for diabetes patients."],"journal":"Wien Klin Wochenschr","authors":["Peric, Slobodan","Stulnig, Thomas M"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435867","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s00508-020-01672-3","keywords":["diabetes complications","diabetes therapy","sars-cov2","telemedicine","viral pneumonia"],"topics":["Prevention"],"weight":1,"_version_":1667521393629069312,"score":9.490897,"similar":[{"pmid":32374541,"title":"[Diabetes and COVID-19 infection].","text":["[Diabetes and COVID-19 infection].","Based on the epidemiological data currently available, diabetes does not seem to be a risk factor for infection with SARS-CoV-2 but may be associated with a more severe course. Diabetes is extremely common in older patients with co-morbidities who are at risk of unfavorable outcomes. As with any other infection, poorly controlled pre-existing diabetes can promote secondary infections and lead to acute complications related to hyperglycemia, worsened itself by the infection. It is important to advise patients to have enough diabetic equipment and supplies at home, to make regular blood glucose self-tests, and to contact a caregiver immediately in case of glycemic imbalance or signs of infection. Antidiabetic therapy may need adjustments following usual sick day rules. Insulin therapy should be considered to treat any persistent hyperglycemia in patients hospitalized for an acute infection.","Rev Med Suisse","Kosinski, Christophe","Zanchi, Anne","Wojtusciszyn, Anne","32374541"],"abstract":["Based on the epidemiological data currently available, diabetes does not seem to be a risk factor for infection with SARS-CoV-2 but may be associated with a more severe course. Diabetes is extremely common in older patients with co-morbidities who are at risk of unfavorable outcomes. As with any other infection, poorly controlled pre-existing diabetes can promote secondary infections and lead to acute complications related to hyperglycemia, worsened itself by the infection. It is important to advise patients to have enough diabetic equipment and supplies at home, to make regular blood glucose self-tests, and to contact a caregiver immediately in case of glycemic imbalance or signs of infection. Antidiabetic therapy may need adjustments following usual sick day rules. Insulin therapy should be considered to treat any persistent hyperglycemia in patients hospitalized for an acute infection."],"journal":"Rev Med Suisse","authors":["Kosinski, Christophe","Zanchi, Anne","Wojtusciszyn, Anne"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374541","source":"PubMed","week":"202019|May 04 - May 10","e_drugs":["Glucose"],"topics":["Prevention"],"weight":1,"_version_":1666138496462487553,"score":243.4759},{"pmid":32388331,"title":"COVID-19 and diabetes mellitus: An unholy interaction of two pandemics.","text":["COVID-19 and diabetes mellitus: An unholy interaction of two pandemics.","BACKGROUND AND AIMS: Diabetes mellitus is associated with poor prognosis in patients with COVID-19. On the other hand, COVID-19 contributes to worsening of dysglycemia in people with diabetes mellitus over and above that contributed by stress hyperglycemia. Herein, we have reviewed the two-way interactions between COVID-19 and diabetes mellitus. METHODS: We have performed an extensive literature search for articles in PubMed, EMBASE and Google Scholar databases till April 25, 2020, with the following keywords: \"COVID-19\", \"SARS-CoV-2\", \"diabetes\", \"diabetes mellitus\", \"SARS\", \"infection\" and \"management of diabetes mellitus\" with interposition of the Boolean operator \"AND\". RESULTS: Compromised innate immunity, pro-inflammatory cytokine milieu, reduced expression of ACE2 and use of renin-angiotensin-aldosterone system antagonists in people with diabetes mellitus contribute to poor prognosis in COVID-19. On the contrary, direct beta-cell damage, cytokine-induced insulin resistance, hypokalemia and drugs used in the treatment of COVID-19 (like corticosteroids, lopinavir/ritonavir) can contribute to worsening of glucose control in people with diabetes mellitus. CONCLUSIONS: The two-way interaction between COVID-19 and diabetes mellitus sets up a vicious cycle wherein COVID-19 leads to worsening of dysglycemia and diabetes mellitus, in turn, exacerbates the severity of COVID-19. Thus, it is imperative that people with diabetes mellitus take all necessary precautions and ensure good glycemic control amid the ongoing pandemic.","Diabetes Metab Syndr","Pal, Rimesh","Bhadada, Sanjay K","32388331"],"abstract":["BACKGROUND AND AIMS: Diabetes mellitus is associated with poor prognosis in patients with COVID-19. On the other hand, COVID-19 contributes to worsening of dysglycemia in people with diabetes mellitus over and above that contributed by stress hyperglycemia. Herein, we have reviewed the two-way interactions between COVID-19 and diabetes mellitus. METHODS: We have performed an extensive literature search for articles in PubMed, EMBASE and Google Scholar databases till April 25, 2020, with the following keywords: \"COVID-19\", \"SARS-CoV-2\", \"diabetes\", \"diabetes mellitus\", \"SARS\", \"infection\" and \"management of diabetes mellitus\" with interposition of the Boolean operator \"AND\". RESULTS: Compromised innate immunity, pro-inflammatory cytokine milieu, reduced expression of ACE2 and use of renin-angiotensin-aldosterone system antagonists in people with diabetes mellitus contribute to poor prognosis in COVID-19. On the contrary, direct beta-cell damage, cytokine-induced insulin resistance, hypokalemia and drugs used in the treatment of COVID-19 (like corticosteroids, lopinavir/ritonavir) can contribute to worsening of glucose control in people with diabetes mellitus. CONCLUSIONS: The two-way interaction between COVID-19 and diabetes mellitus sets up a vicious cycle wherein COVID-19 leads to worsening of dysglycemia and diabetes mellitus, in turn, exacerbates the severity of COVID-19. Thus, it is imperative that people with diabetes mellitus take all necessary precautions and ensure good glycemic control amid the ongoing pandemic."],"journal":"Diabetes Metab Syndr","authors":["Pal, Rimesh","Bhadada, Sanjay K"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388331","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.dsx.2020.04.049","keywords":["covid-19","cytokines","diabetes mellitus","t1dm","t2dm"],"locations":["Boolean"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666428892665085952,"score":239.0998},{"pmid":32392473,"title":"The challenges of COVID-19 for people living with diabetes: considerations for digital health.","text":["The challenges of COVID-19 for people living with diabetes: considerations for digital health.","UNSTRUCTURED: The coronavirus disease 2019 (COVID-19) is a global pandemic that significantly impacts people living with diabetes. Diabetes-related factors of glycemic control, medication pharmacodynamics, social distancing, and insulin access can impact the severity of COVID-19 infection. In this commentary, we explore how digital health can support the diabetes community through the pandemic. For those living with diabetes, digital health presents the opportunity to access care with greater convenience while not having to expose themselves to infection in an in-person clinic. Digital diabetes applications can increase agency in self-care and produce clinically significant improvement in glycemic control through facilitating the capture of diabetes device data. However, the ability to share these data back to the clinic to inform virtual care and enhance diabetes coaching and guidance remains a challenge. In the end, it requires an unnecessarily high level of technical sophistication on the clinic's part and on those living with diabetes to routinely use their diabetes device data in clinic visits, virtual or otherwise. As the world comes together to fight the COVID-19 pandemic, close collaboration among the global diabetes community is critical to understand and manage the sustained impact of the pandemic on people living with diabetes.","JMIR Diabetes","Gamble, Anissa","Pham, Quynh","Goyal, Shivani","Cafazzo, Joseph A","32392473"],"abstract":["UNSTRUCTURED: The coronavirus disease 2019 (COVID-19) is a global pandemic that significantly impacts people living with diabetes. Diabetes-related factors of glycemic control, medication pharmacodynamics, social distancing, and insulin access can impact the severity of COVID-19 infection. In this commentary, we explore how digital health can support the diabetes community through the pandemic. For those living with diabetes, digital health presents the opportunity to access care with greater convenience while not having to expose themselves to infection in an in-person clinic. Digital diabetes applications can increase agency in self-care and produce clinically significant improvement in glycemic control through facilitating the capture of diabetes device data. However, the ability to share these data back to the clinic to inform virtual care and enhance diabetes coaching and guidance remains a challenge. In the end, it requires an unnecessarily high level of technical sophistication on the clinic's part and on those living with diabetes to routinely use their diabetes device data in clinic visits, virtual or otherwise. As the world comes together to fight the COVID-19 pandemic, close collaboration among the global diabetes community is critical to understand and manage the sustained impact of the pandemic on people living with diabetes."],"journal":"JMIR Diabetes","authors":["Gamble, Anissa","Pham, Quynh","Goyal, Shivani","Cafazzo, Joseph A"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392473","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.2196/19581","topics":["Prevention"],"weight":1,"_version_":1666528580168843264,"score":229.47061},{"pmid":32405783,"title":"Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.","text":["Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.","The coronavirus disease 2019 (COVID-19) pandemic has emerged as one of the greatest challenges faced by humankind in the recent past. People with diabetes and related comorbidities are at increased risk of its complications and of COVID-19-related death. Older age, multi-morbidity, hyperglycaemia, cardiac injury and severe inflammatory response are predictors of poor outcome. The complex interplay between COVID-19, diabetes and the effects of related therapies is being explored. Most patients experience a mild illness with COVID-19, while people with diabetes are at increased risk of severe disease. Optimising glycaemic control and adopting measures to prevent disease spread are critical aspects. The management of mild disease is supportive, while very many immunomodulatory and antiviral therapies are being investigated for the treatment of severe disease. Several of these agents have specific considerations for use in people with diabetes. Since mass population lockdowns are considered a key step in controlling disease spread, it follows that, in addition to the direct vulnerability to severe COVID-19, people with diabetes can be affected by limited access to healthcare, insulin, other medications and blood glucose monitoring equipment. Measures to prevent disease spread at the individual and community level are the key to mitigating the rapidly escalating pandemic, while agents for chemoprophylaxis and vaccines are being explored. People with diabetes should be recognised as a vulnerable group for complicated disease and are at risk during times of disturbed social systems. Strategies are needed to safeguard the health of patients with diabetes during the pandemic. This review summarises the current knowledge and perceived challenges for prevention and management of COVID-19 in people with diabetes.","Diabetologia","Katulanda, Prasad","Dissanayake, Harsha A","Ranathunga, Ishara","Ratnasamy, Vithiya","Wijewickrama, Piyumi S A","Yogendranathan, Nilukshana","Gamage, Kavinga K K","de Silva, Nipun L","Sumanatilleke, Manilka","Somasundaram, Noel P","Matthews, David R","32405783"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic has emerged as one of the greatest challenges faced by humankind in the recent past. People with diabetes and related comorbidities are at increased risk of its complications and of COVID-19-related death. Older age, multi-morbidity, hyperglycaemia, cardiac injury and severe inflammatory response are predictors of poor outcome. The complex interplay between COVID-19, diabetes and the effects of related therapies is being explored. Most patients experience a mild illness with COVID-19, while people with diabetes are at increased risk of severe disease. Optimising glycaemic control and adopting measures to prevent disease spread are critical aspects. The management of mild disease is supportive, while very many immunomodulatory and antiviral therapies are being investigated for the treatment of severe disease. Several of these agents have specific considerations for use in people with diabetes. Since mass population lockdowns are considered a key step in controlling disease spread, it follows that, in addition to the direct vulnerability to severe COVID-19, people with diabetes can be affected by limited access to healthcare, insulin, other medications and blood glucose monitoring equipment. Measures to prevent disease spread at the individual and community level are the key to mitigating the rapidly escalating pandemic, while agents for chemoprophylaxis and vaccines are being explored. People with diabetes should be recognised as a vulnerable group for complicated disease and are at risk during times of disturbed social systems. Strategies are needed to safeguard the health of patients with diabetes during the pandemic. This review summarises the current knowledge and perceived challenges for prevention and management of COVID-19 in people with diabetes."],"journal":"Diabetologia","authors":["Katulanda, Prasad","Dissanayake, Harsha A","Ranathunga, Ishara","Ratnasamy, Vithiya","Wijewickrama, Piyumi S A","Yogendranathan, Nilukshana","Gamage, Kavinga K K","de Silva, Nipun L","Sumanatilleke, Manilka","Somasundaram, Noel P","Matthews, David R"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405783","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s00125-020-05164-x","keywords":["covid-19","coronavirus","diabetes","sars-cov-2"],"topics":["Prevention"],"weight":1,"_version_":1666802845436870656,"score":208.31247},{"pmid":32471607,"title":"Diabetes and COVID-19.","text":["Diabetes and COVID-19.","According to previous reports, diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19. But is diabetes per se a risk factor that increases the probability of getting the virus? This paper will discuss this point. There are not many research data on antidiabetic drugs in this context. The potential influence of glucose-lowering agents on the severity of COVID-19 has not been described yet. Dipeptidylpeptidase-4 (DPP-4) is a cell surface protein ubiquitously expressed in many tissues and it is also a soluble molecule found in serum/plasma fluids. DPP-4 is involved in infection of cells by some viruses. This paper reviews data about the use of DPP-4 inhibitors and others diabetes drugs on COVID-19 patients. As such, no available evidence has yet suggested that glucose-lowering drugs - including those targeting DPP4-related pathways - produce any significant harm or benefit in the context of human infections. However, insulin must remain the first-choice agent in the management of critically ill-hospitalized patients, while it is recommended to suspend other agents in unstable patients. This paper provides related French and international recommendations for people with diabetes who got infected by COVID-19 and upholds that infections may alter glucose control and may require additional vigilance.","Therapie","Bouhanick, Beatrice","Cracowski, Jean-Luc","Faillie, Jean-Luc","32471607"],"abstract":["According to previous reports, diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19. But is diabetes per se a risk factor that increases the probability of getting the virus? This paper will discuss this point. There are not many research data on antidiabetic drugs in this context. The potential influence of glucose-lowering agents on the severity of COVID-19 has not been described yet. Dipeptidylpeptidase-4 (DPP-4) is a cell surface protein ubiquitously expressed in many tissues and it is also a soluble molecule found in serum/plasma fluids. DPP-4 is involved in infection of cells by some viruses. This paper reviews data about the use of DPP-4 inhibitors and others diabetes drugs on COVID-19 patients. As such, no available evidence has yet suggested that glucose-lowering drugs - including those targeting DPP4-related pathways - produce any significant harm or benefit in the context of human infections. However, insulin must remain the first-choice agent in the management of critically ill-hospitalized patients, while it is recommended to suspend other agents in unstable patients. This paper provides related French and international recommendations for people with diabetes who got infected by COVID-19 and upholds that infections may alter glucose control and may require additional vigilance."],"journal":"Therapie","authors":["Bouhanick, Beatrice","Cracowski, Jean-Luc","Faillie, Jean-Luc"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471607","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.therap.2020.05.006","keywords":["covid-19","dpp-4 inhibitors","diabetes","diabetes drugs","epidemiology","recommendations"],"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Treatment"],"weight":1,"_version_":1668255193429442560,"score":201.38608}]}